Q2 2026 saw $15B in revenue (up 1% YoY), with strong non-COVID growth and adjusted EPS of $0.77. Full-year guidance was raised, cost savings initiatives expanded, and key pipeline assets in oncology, obesity, and immunology advanced. Dividend commitment remains firm.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.